Nissan Chemical Industries Limited

Hiroshi Nagai

Yusuke Shintani

Tsuneo Watanabe

Yuichi Hirai

Yukihiro Shigeta

Masato Horikawa

Yutaka Hirokawa

Junji Kamon

Michiaki Adachi

Noriko Saito

Kazuya Takeuchi

Yusuke Inaba

Megumi Io

Kei Nagae

Jun Egi

Megumi Ueno

Daiki Takahashi

Koichi Yasutake

Takeshi Kawazu

There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example Ris H or Calkoxy, etc., each of Land Lis independently a single bond or NR, etc., Lis Calkylene, etc., A is Caryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is Ccycloalkylene, etc., D is Caryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.

Triazinone compound and T-type calcium channel inhibitor

Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases. 

Pyridazinone compounds and P2X7 receptor inhibitors

Growing community of inventors

Funabashi, Japan

Hiroshi Nagai